THE CHROMOSOME | Clinical Content Series
IGF-1 Imbalance
Back to Case Studies ArchiveCase Study
He was 46 years old and had been an athlete in his twenties. Not professionally, but in the way that many Pakistani men of his generation had been physically active, strong, and metabolically resilient without conscious effort or deliberate intervention. He had played cricket through his late twenties, squash through his early thirties, and had maintained a lean, muscular physique until his late thirties with what he described as minimal dietary discipline and no particular exercise regimen beyond the sport he enjoyed.
Then, across a period of roughly five years beginning in his early forties, everything had changed in a way that felt less like ageing and more like a system failure. He had gained 28 kilograms. The muscle had not simply reduced, it had been replaced, as though exchanged, by fat that settled in the visceral compartment with a permanence that no amount of return to physical activity had disturbed. He had resumed cricket at 43 in an attempt to reverse what was happening. He had been injured twice within the first month, muscle strains that healed slowly, joints that ached after activity that had previously produced no discomfort, a recovery capacity that bore no resemblance to what he had experienced in his athletic years. He had stopped trying after the second injury and had concluded that his body had simply aged beyond the point of athletic participation.
He had not aged beyond it. His cellular repair machinery had been deprived of the hormone that drives it.
When I evaluated his complete hormonal profile the finding that anchored the entire clinical picture was his IGF-1. Insulin-like growth factor 1, the primary mediator of growth hormone's anabolic effects, produced predominantly by the liver in response to growth hormone stimulation, and the hormone through which virtually every tissue maintenance, cellular repair, and body composition regulation function of growth hormone is actually executed at the cellular level. His IGF-1 was 67 nanograms per millilitre. The lower limit of the age appropriate reference range for a man of his age is 115. His IGF-1 was not borderline low. It was critically, severely suppressed, at a level I associate with patients who have been functionally growth hormone deficient for years and whose tissues have been operating without adequate anabolic hormonal support for a period sufficient to produce the clinical picture sitting across from me.
IGF-1 imbalance in Pakistani obesity patients presents in two distinct clinical patterns that produce different metabolic consequences and require different therapeutic approaches, and understanding which pattern is operating is essential before any intervention is initiated. The first pattern, low IGF-1 in the context of visceral obesity, insulin resistance, and growth hormone axis suppression, is the pattern this patient demonstrated. It reflects the suppression of growth hormone pulsatility by the combined effects of visceral fat, elevated insulin, dysregulated cortisol, and disrupted sleep, producing an IGF-1 deficit that drives muscle loss, impaired cellular repair, accelerated visceral fat accumulation, and the metabolic deterioration of functional growth hormone deficiency. The second pattern, elevated IGF-1 in the context of insulin resistance and compensatory growth hormone hypersecretion, is less common but clinically important because elevated IGF-1 carries its own distinct risk profile, including association with thyroid nodule formation, colon polyp development, and the cellular proliferation pathways that increase cancer risk.
In Pakistani patients, the low IGF-1 pattern is substantially more prevalent, reflecting the combined suppressive effects of visceral obesity, hyperinsulinaemia, cortisol dysregulation, sleep disruption, and the FTO associated growth hormone axis impairment that I have described in the context of Disorder 09. What makes IGF-1 a distinct and separately important measurement from growth hormone itself is the hepatic dimension, IGF-1 is produced by the liver, and the non alcoholic fatty liver disease that is extremely prevalent in Pakistani obesity patients impairs hepatic IGF-1 production independently of growth hormone secretion. A Pakistani patient can have adequate growth hormone output from the pituitary and still have severely suppressed IGF-1 because the liver through which that growth hormone signal must be converted to IGF-1 is fatty, inflamed, and metabolically dysfunctional. Measuring growth hormone without IGF-1, or interpreting IGF-1 without assessing hepatic function, produces an incomplete and potentially misleading picture of anabolic hormonal status.
His liver enzymes were mildly elevated, consistent with the early fatty infiltration that his metabolic profile predicted. His insulin resistance was significant. His cortisol pattern was dysregulated. His sleep was severely insufficient, averaging five and a half hours per night across a work week that left no room for the sleep that the majority of his daily growth hormone and IGF-1 production depended upon. His testosterone was at the lower end of the normal range, reflecting both the visceral fat driven aromatisation and the shared anabolic hormonal suppression that affects both testosterone and the growth hormone IGF-1 axis simultaneously in the context of visceral obesity and metabolic stress.
The FTO gene's influence on IGF-1 in Pakistani patients operates through two principal pathways. First, the FTO associated predisposition to visceral fat accumulation suppresses growth hormone pulsatility, the hypothalamic signal that drives hepatic IGF-1 production, through the somatostatin enhancing effects of elevated free fatty acids from visceral lipolysis and through the direct growth hormone suppressive effects of visceral inflammatory cytokines. Second, the FTO associated predisposition to non alcoholic fatty liver disease impairs the hepatic IGF-1 production capacity independently of growth hormone stimulation, reducing the liver's ability to convert adequate growth hormone signal into the IGF-1 output that peripheral tissues require. Pakistani patients with significant visceral obesity and hepatic fat accumulation therefore experience IGF-1 deficiency that is driven from both ends of the growth hormone IGF-1 axis simultaneously, suppressed stimulation from above and impaired production from below, producing a degree of anabolic hormonal deficiency that their growth hormone levels alone would not reveal.
We addressed his IGF-1 deficiency through the comprehensive metabolic framework that the dual axis suppression required. Sleep restoration was the single most urgent intervention, reinstating the slow wave sleep dependent growth hormone pulsatility that was producing the majority of his IGF-1 stimulation deficit. Visceral fat reduction removed the somatostatin enhancing and growth hormone suppressive effects of the visceral fat load. Hepatic health restoration, through insulin resistance treatment, visceral fat reduction, and targeted nutritional support for hepatic function, addressed the production side of the IGF-1 deficit by restoring the liver's capacity to convert growth hormone stimulation into adequate IGF-1 output. Insulin resistance treatment removed the hyperinsulinaemic suppression of growth hormone pulsatility. Cortisol recalibration removed the cortisol mediated somatostatin enhancement that had been additionally suppressing growth hormone release. Where peptide based growth hormone secretagogues were clinically appropriate within this comprehensive framework, they were incorporated to support the restoration of endogenous growth hormone pulsatility rather than to replace it.
Sixteen months later his IGF-1 had risen to 138 nanograms per millilitre, within the age appropriate reference range for the first time in years. He had lost 24 kilograms. His muscle had returned in a way that the preceding eighteen months of resumed physical activity had been unable to produce, because physical activity alone cannot drive muscle recovery in a patient without adequate IGF-1 to mediate the anabolic response to exercise. His recovery from physical exertion had normalised, the muscle strains and joint discomfort that had ended his cricket return were absent from the resumption of physical activity that his restored anabolic hormonal environment now supported. His liver enzymes had normalised. His sleep was transformed. His energy, his physical resilience, and his sense of his own biological capacity had returned in a way he described as genuinely unexpected, he had concluded that the athletic body he had inhabited in his thirties was permanently lost. It was not lost. It was hormonally deprived.
FAQs
Insulin-like growth factor 1 is the primary mediator of growth hormone's anabolic effects, produced predominantly by the liver in response to growth hormone stimulation and acting on virtually every tissue in the body to drive muscle protein synthesis, fat oxidation, cellular repair, bone density maintenance, immune function, and cognitive performance. It is the hormone through which growth hormone's effects are actually executed at the cellular level, making its measurement more directly relevant to tissue level anabolic status than growth hormone measurement alone. In Pakistani obesity patients, IGF-1 measurement is essential because the combination of visceral fat driven growth hormone suppression and fatty liver driven hepatic IGF-1 production impairment produces IGF-1 deficiency from both ends of the axis simultaneously, a pattern that growth hormone measurement alone, without IGF-1, would fail to fully characterise.
Visceral fat suppresses IGF-1 in Pakistani patients through converging mechanisms at both ends of the growth hormone IGF-1 axis. At the hypothalamic pituitary level, the elevated free fatty acids released by visceral lipolysis enhance somatostatin tone, the inhibitory signal that suppresses growth hormone release from the pituitary, reducing the growth hormone stimulation that drives hepatic IGF-1 production. The inflammatory cytokines generated by visceral fat simultaneously suppress pituitary growth hormone secretion through direct cytokine mediated hypothalamic inhibition. At the hepatic level, the non alcoholic fatty liver disease driven by visceral fat accumulation impairs the liver's capacity to convert growth hormone stimulation into IGF-1 output, reducing production even when the growth hormone signal reaching the liver is adequate. Pakistani patients with significant visceral fat therefore experience IGF-1 suppression from above and below simultaneously, a dual axis suppression that produces more severe IGF-1 deficiency than either mechanism alone would create.
The FTO gene at Chromosome 16q12.2 contributes to IGF-1 imbalance in Pakistani patients through its promotion of the visceral fat accumulation and non alcoholic fatty liver disease that suppress IGF-1 from both ends of the growth hormone IGF-1 axis. The FTO associated predisposition to visceral fat accumulation at lower body weight thresholds creates the dual axis IGF-1 suppression earlier and more severely than in Western populations at equivalent degrees of obesity. The FTO associated predisposition to hepatic fat accumulation, through insulin resistance and visceral fat driven portal inflammatory exposure, impairs hepatic IGF-1 production capacity at lower degrees of liver fat infiltration than Western clinical models anticipate. Dr. Zaar measures IGF-1 as a standard component of every Pakistani obesity hormonal assessment, because the FTO associated dual mechanism of IGF-1 suppression makes it a metabolically significant finding in a substantial proportion of evaluated patients.
IGF-1 is the primary anabolic signal through which exercise induced muscle protein synthesis is executed, it binds to IGF-1 receptors on muscle satellite cells, stimulating their proliferation and differentiation into new muscle fibres in response to the mechanical stress that exercise provides. Without adequate IGF-1 at the receptor level, the muscle protein synthesis stimulus that exercise generates cannot be translated into actual muscle tissue growth and repair, the mechanical signal is present but the anabolic hormonal response it requires is absent. Pakistani obesity patients with severe IGF-1 deficiency who attempt exercise therefore experience the exertion and the discomfort of physical activity without the muscle recovery and growth that the activity should produce, leading to injury, prolonged soreness, and the demoralising conclusion that their body is no longer capable of responding to exercise. It is not incapable. It is anabolically deprived, and restoring IGF-1 is the prerequisite to productive physical rehabilitation.
The majority of daily growth hormone secretion, and therefore the majority of the hepatic IGF-1 stimulation that growth hormone provides, occurs during slow wave sleep, the deepest stage of the sleep cycle. Each hour of sleep below the seven to nine hour optimal range reduces the slow wave sleep available for growth hormone secretion, progressively depleting IGF-1 stimulation with each night of restriction. In Pakistani patients sleeping five to six hours nightly, which is the norm rather than the exception in Pakistani urban professional life, this nightly IGF-1 stimulation deficit accumulates across months and years into the chronic IGF-1 deficiency that Dr. Zaar identifies as a standard finding in Pakistani obesity patients with inadequate sleep duration. The clinical urgency of sleep restoration in these patients extends beyond the direct benefits of sleep itself, it is the most time efficient and most metabolically impactful single intervention available for IGF-1 restoration in sleep deprived Pakistani patients.
Elevated IGF-1, the less common but clinically important second pattern of IGF-1 imbalance, carries a distinct risk profile that includes association with increased risk of thyroid nodule formation, colorectal polyp development, breast tissue proliferation, and the cellular growth pathway activation that underlies increased cancer susceptibility. In Pakistani patients, elevated IGF-1 may occur in the context of insulin resistance driven compensatory growth hormone hypersecretion, where the hyperinsulinaemia of severe insulin resistance paradoxically drives elevated IGF-1 through insulin mediated IGF-1 receptor activation and reduced IGF binding protein production. Dr. Zaar evaluates IGF-1 in Pakistani obesity patients not only for deficiency but for excess, because elevated IGF-1 in the context of insulin resistance and visceral obesity requires a different therapeutic approach and a different risk monitoring framework than IGF-1 deficiency.
The liver produces IGF-1 through a process that requires functional hepatocytes, liver cells operating with adequate metabolic efficiency, adequate receptor sensitivity to growth hormone stimulation, and adequate biosynthetic capacity for the IGF-1 protein itself. Non alcoholic fatty liver disease impairs all three requirements simultaneously. Fatty infiltration of hepatocytes reduces their metabolic efficiency and biosynthetic capacity. The hepatic inflammation of steatohepatitis impairs growth hormone receptor expression on hepatocyte surfaces, reducing the sensitivity of liver cells to the growth hormone stimulation that should drive IGF-1 production. And the insulin resistance of the fatty liver creates a hepatic metabolic environment in which IGF-1 synthetic pathways are downregulated as part of the broader hepatic metabolic dysfunction. Pakistani patients with non alcoholic fatty liver disease therefore have an impaired IGF-1 production capacity that is restored only when hepatic health is meaningfully recovered, making hepatic restoration a prerequisite to complete IGF-1 normalisation in affected patients.
IGF-1 restoration in Pakistani obesity patients is achievable through comprehensive metabolic intervention in the majority of cases, without requiring direct exogenous growth hormone administration, which carries regulatory and safety considerations that make it inappropriate as a first line approach in the absence of confirmed pituitary pathology. Sleep restoration reinstates the slow wave sleep dependent growth hormone pulsatility that provides the primary IGF-1 stimulation. Visceral fat reduction removes the somatostatin enhancement and hepatic impairment that suppress IGF-1 from both ends of the axis. Hepatic health restoration through insulin resistance treatment and fat reduction recovers the hepatic production capacity that translates growth hormone stimulation into adequate IGF-1 output. Cortisol recalibration removes the growth hormone suppressive somatostatin enhancement of cortisol excess. Where these foundational interventions produce insufficient IGF-1 restoration, peptide based growth hormone secretagogues, which stimulate endogenous growth hormone production rather than replacing it, are incorporated into THE CHROMOSOME protocol as a precisely calibrated addition to the comprehensive metabolic framework rather than as a replacement for it.